Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRVANA-LUNG: Pembrolizumab, Chemotherapy, and Radiotherapy in Advanced NSCLC
NCT03774732Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Jan 2018
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Unicancer. Started Jan 2018; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03774732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774732.